Other Causes of Hepatic Steatosis Beyond NAFLD
When evaluating hepatic steatosis, clinicians must systematically exclude alcohol-related liver disease, medications, viral hepatitis (particularly HCV genotype 3), and rare metabolic/genetic disorders before confirming a diagnosis of NAFLD. 1, 2
Alcohol-Related Steatosis
- Significant alcohol consumption is defined as >21 drinks per week in men or >14 drinks per week in women, which indicates alcohol-related liver disease rather than NAFLD 1, 3
- Even alcohol consumption below these thresholds contributes to hepatic fat accumulation, particularly with binge drinking patterns 1
- Use sensitive biomarkers when alcohol history is unreliable: urine ethyl glucuronide (detects use within 3-5 days) or blood phosphatidylethanol (detects use within 1-2 weeks) 1
- The AUDIT-C questionnaire should be incorporated to standardize screening for alcohol misuse and binge drinking 2
Medication-Induced Steatosis
Approximately 2% of steatosis cases are attributable to prescribed medications, requiring a comprehensive drug history in all patients 2
High-Risk Medications:
- Antiarrhythmics: Amiodarone causes hepatotoxicity with acute centrolobular confluent hepatocellular necrosis and chronic liver enzyme elevations 2, 4
- Anticonvulsants: Carbamazepine, sodium valproate 2
- Anti-metabolites: Methotrexate (particularly with cumulative doses >1.5 grams), 5-Fluorouracil 2, 5
- Hormone modulators: Tamoxifen (estrogen receptor modulator), corticosteroids 1, 2, 6
- Antiretrovirals: Efavirenz and other HIV medications 2
- Analgesics: NSAIDs 2
Methotrexate requires special attention: hepatotoxicity appears after prolonged use (≥2 years) and total cumulative doses ≥1.5 grams, enhanced by alcoholism, obesity, diabetes, and advanced age 5
Viral Hepatitis
- Hepatitis C genotype 3 is specifically associated with increased rates of steatosis and must be excluded with viral serology in all patients undergoing evaluation for suspected NAFLD 1, 2
- HCV-related steatosis impacts both fibrosis progression and treatment response 7
Rare Metabolic and Genetic Causes
These should be considered particularly in lean individuals with steatosis who lack cardiometabolic risk factors 1:
Lipid Metabolism Disorders:
Body Composition Disorders:
- Lipodystrophy (both HIV-related and non-HIV forms) 1
Other Metabolic Conditions:
- Wilson's disease (copper metabolism disorder) 3
- Hemochromatosis (iron overload) - elevated ferritin and transferrin saturation warrant HFE gene testing 3
- Alpha-1 antitrypsin deficiency 2
Nutritional and Gastrointestinal Causes
- Total parenteral nutrition 1, 3
- Severe malnutrition (fully reversible with refeeding and does not cause chronic liver disease) 3, 8
Endocrine Disorders
- Hypothyroidism should be evaluated as part of the comprehensive metabolic screen 1
Toxin Exposures
- Vinyl chloride and other industrial toxins 1
Systematic Diagnostic Approach
A comprehensive metabolic and serological screen must be undertaken to consolidate the NAFLD diagnosis and exclude co-existent liver disease 2:
Required Laboratory Evaluation:
- Autoimmune markers (ANA, anti-smooth muscle antibody) 2
- Viral serology (hepatitis B surface antigen, hepatitis C antibody) 2
- Iron studies (ferritin, transferrin saturation) 2
- Copper studies (ceruloplasmin, 24-hour urine copper) 2
- Alpha-1 antitrypsin level 2
- Thyroid function tests 1
Critical Pitfall to Avoid:
Do not rely solely on liver enzyme levels - they can be normal in patients with significant NAFLD, and mildly elevated ferritin is common in NAFLD without indicating iron overload 3, 9